This study aims to collect and analyze clinical data of daptomycin to explore the efficacy and safety of daptomycin in the treatment of Gram-positive bacterial infections. And optimize the dosing regimen based on these data.
With the gradual increase in the detection rate of drug-resistant bacteria, bloodstream infections, skin and soft tissue infections, infective endocarditis and other infectious diseases caused by MRSA, MRCNS, and VRE have greatly increased patient mortality and medical burden. Daptomycin has strong anti-bacterial activity and rapid sterilization. It is almost 100% sensitive to common Gram-positive bacteria. Both domestic and foreign guidelines recommend its use for the treatment of infectious diseases such as bacteremia, central venous catheter-related bloodstream infections, infective endocarditis, skin and soft tissue infections, bone and joint infections，and so on. However, there is a lack of actual clinical use of daptomycin in China, as well as efficacy and safety assessments based on real world data. The purpose of this study is to collect and analyze data on the use of daptomycin in the real world. The clinical cure rate and inefficiency, temperature drop time, 28-day mortality rate are the primary outcome measures, and the overall incidence of adverse events, the results of CPK monitoring and its correlation with dose, renal function, length of hospital stay, and treatment costs are secondary outcome measures to investigate the efficacy and safety of daptomycin in the treatment of gram-positive bacterial infection.
Study Type
OBSERVATIONAL
Enrollment
2,000
According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGClinical efficacy rate
Clinical efficacy includes clinical cure and clinical improvement.
Time frame: 1 day of the end of treatment
Clinical cure rate
Clinical cure was defined as that after the end of treatment, all the selected symptoms and signs had disappeared or completely returned to normal, and all the non-microbiological indicators, such as imaging and laboratory examination, had returned to normal.
Time frame: 14 days of the end of treatment
Treatment failure rate
Treatment failure includes one of the following conditions: 1. After the end of the treatment, all the symptoms and signs of the patients at the time of inclusion continued or worsened. 2. Recurrence. 3. Termination of treatment due to adverse reactions.
Time frame: 28 days of the end of treatment
Time for body temperature to return to normal.
During the use of daptomycin, take body temperature records.
Time frame: 14 days of the end of treatment
28-Day Mortality Rate
Record the number of deaths 28 days after the end of treatment
Time frame: 28 days of the end of treatment
Bacteria clearance rate (if available, such as bacteremia)
Bacterial clearance includes clearance and hypothetical clearance. Bacterial clearance is defined as the specimens from the original infection site after treatment have not cultivated the pathogenic bacteria of the original infection. When the patient's symptoms and signs disappear so that cultivable materials cannot be obtained, or the method of obtaining specimens is too invasive for the recovered patient, the bacteriological result is considered to be a hypothetical clearance.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 1 day of the end of treatment
The overall incidence of adverse events
Adverse events refer to adverse medical events that occur after patients or clinical trial subjects receive a drug, but they do not necessarily have a causal relationship with treatment.
Time frame: 14 days of the end of treatment
Monitor creatine phosphokinase（CPK） levels
Record the CPK monitoring results.
Time frame: 14 days of the end of treatment
hospital stays
Time frame: 28 days of the end of treatment